News

Article

Patheon Acquires IRIX Pharmaceuticals

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

 

Patheon announced on March 4 that it has reached a definitive agreement to acquire Florence, SC-based IRIX Pharmaceuticals, which specializes in difficult-to-manufacture APIs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the transaction in 60 days.

Patheon reports that with the acquisition, it secures additional API development and manufacturing services in the United States, including high-potency (SafeBridge Class IV-certified) and controlled substances (Schedule 1-4). IRIX has facilities for the optimization of chemical processes and scale up for commercial API manufacturing in Florence and Greenville, SC.

The combined companies will offer an array of process technologies, including biocatalysis, homogeneous catalysis, and microreactors and are positioned to address a range of supply chain issues for customers, according to a press statement.

Source: Patheon

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content